2024 was the year of pilot projects. Pharma companies experimented with GenAI, tested narrow use cases, and debated its potential. In 2025, the conversation has shifted. Leaders are no longer asking if GenAI belongs in life sciences. The question now is where and how.
That shift matters. GenAI is not just a shiny new tool. Done right, it can transform how pharmaceutical companies accelerate R&D, manage compliance-heavy processes, and improve the daily lives of both field teams and patients. But done wrong, it risks creating inefficiencies, compliance headaches, or worse, regulatory pushback.
At Newpage, we see two patterns emerge when working with pharma and biotech teams. First, there are a handful of use cases that are mature, safe, and ready to deliver ROI right now. Second, there are others that are exciting but still require careful guardrails around compliance, data privacy, and oversight. Knowing which is which makes all the difference.
Think about it this way:
- Some teams are already using GenAI to streamline the flood of medical information requests they receive every day, cutting response times dramatically.
- Others are piloting GenAI-driven patient support programs, creating more personalized, multilingual engagement at scale.
- Meanwhile, regulatory and safety teams are cautiously exploring how GenAI can support literature monitoring, case narratives, and document drafting, areas with enormous upside but equally high stakes.
None of this is science fiction anymore. These are practical, high-impact workflows happening today in pharma. The challenge is deciding which ones your organization is truly ready to scale in 2025.
That is where strategy comes in. Implementation is not just about deploying a language model. It is about building the right governance, fine-tuning prompts, integrating GenAI into existing Salesforce, Veeva, or Argus environments, and preparing teams to adopt it responsibly. The payoff can be huge: faster trials, lighter workloads, and more trusted engagement with healthcare professionals and patients. But only if it is done with the right foundation.
In our latest blog, we break down the seven most important GenAI use cases pharma leaders should focus on in 2025. We look at what is mature today, what still requires oversight, and how to approach adoption in a way that is both ethical and scalable.
👉 Read the full article here: The 7 Best Ways for Pharmaceutical Companies to Use GenAI in 2025
2025 is not the year to keep experimenting on the sidelines. It is the year to move from pilot to platform and to do it in a way that drives measurable value while keeping compliance at the center.
Top comments (0)